A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

M. K. Wallack, K. McNally, M. Michaelides, J. Bash, A. Bartolucci, H. Siegler, C. Balch, H. Wanebo

Research output: Contribution to journalArticlepeer-review

Abstract

Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalAmerican Surgeon
Volume52
Issue number3
StatePublished - May 21 1986
Externally publishedYes

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)'. Together they form a unique fingerprint.

Cite this